ERBB2 and metastatic neoplasm: Proliferation of SKBR-3 cells is sensitive to trastuzumab [23], whereas proliferation of JIMT-1 cells, a line with HER2 gene amplification but moderate expression and derived from a breast cancer patient whose metastatic tumor had progressed while on trastuzumab, is insensitive to trastuzumab [28].